Gut microbiota, inflammation and colorectal cancer

Genes and Diseases

Volumn 3, Issue 2, 2016, Pages 130-143

  Sun, Jun ^a   Kato, Ikuko ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta catenin; Colon cancer; Cytokines; Dysbiosis; Epidemiologic; Gut barrier; Human microbiome; Inflammation

Indexed keywords

BACTERIAL VIRULENCE; BACTEROIDES FRAGILIS; CANCER PREVENTION; CANCER RISK; COLORECTAL CANCER; DYSBIOSIS; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; FUNGUS; FUSOBACTERIUM NUCLEATUM; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; INTESTINE FLORA; NONHUMAN; REVIEW; SALMONELLA ENTERICA; SPECIES RICHNESS; TUMOR GROWTH; VIRUS;

EID: 84978132171     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2016.03.004     Document Type: Review

References (165)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2012. 2014; based on November 2014 SEER Data Submission, Posted to the SEER Web Site: 2015, Accessed 1.07.15. http://seer.cancer.gov/csr/1975_2011/.
2. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136:E359-E386.
3. Tjalsma H., Boleij A., Marchesi J.R., Dutilh B.E. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012, 10:575-582.
4. Joossens M., Huys G., Cnockaert M., et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011, 60:631-637.
5. Marchesi J.R., Dutilh B.E., Hall N., et al. Towards the human colorectal cancer microbiome. PLoS One 2011, 6:e20447.
6. Albenberg L., Esipova T.V., Judge C.P., et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 2014, 147. 1055-1063.e1058.
7. Mira-Pascual L., Cabrera-Rubio R., Ocon S., et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol 2015, 50:167-179.
8. Sobhani I., Tap J., Roudot-Thoraval F., et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011, 6:e16393.
9. Wang T., Cai G., Qiu Y., et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 2012, 6:320-329.
10. Wu N., Yang X., Zhang R., et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol 2013, 66:462-470.
11. Geng J., Fan H., Tang X., Zhai H., Zhang Z. Diversified pattern of the human colorectal cancer microbiome. Gut Pathog 2013, 5:1-5.
12. Geng J., Song Q., Tang X., et al. Co-occurrence of driver and passenger bacteria in human colorectal cancer. Gut Pathog 2014, 6:1-5.
13. Ahn J., Sinha R., Pei Z., et al. Human gut microbiome and risk for colorectal cancer. J Nat Cancer Inst 2013, 105:1907-1911.
14. Chen W., Liu F., Ling Z., Tong X., Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012, 7:e39743.
15. Weir T.L., Manter D.K., Sheflin A.M., Barnett B.A., Heuberger A.L., Ryan E.P. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 2013, 8:e70803.
16. Kostic A.D., Gevers D., Pedamallu C.S., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012, 22:292-298.
17. Moellering R.C., Watson B.K., Kunz L.J. Endocarditis due to group D streptococci. Comparison of disease caused by Streptococcus bovis with that produced by the enterococci. Am J Med 1974, 57:239-250.
18. Corredoira J., Alonso M.P., Coira A., et al. Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis 2008, 27:285-291.
19. Corredoira J., Alonso M.P., Coira A., Varela J. Association between Streptococcus infantarius (formerly S. bovis II/1) bacteremia and noncolonic cancer. J Clin Microbiol 2008, 46:1570.
20. Schlegel L., Grimont F., Collins M.D., Régnault B., Grimont P.A., Bouvet A. Streptococcus infantarius sp. nov., Streptococcus infantarius subsp. infantarius subsp. nov. and Streptococcus infantarius subsp. coli subsp. nov., isolated from humans and food. Int J Syst Evol Microbiol 2000, 50:1425-1434.
21. Ribeiro M.L., Godoy A.P.O., Benvengo Y.H.B., Ecclissato C.C., Mendonça S., Pedrazzoli J. The influence of endoscopic procedures upon the contamination of Helicobacter pylori cultures. Arq Gastroenterol 2004, 41:100-103.
22. Randazzo C.L., Vaughan E.E., Caggia C. Artisanal and experimental Pecorino Siciliano cheese: microbial dynamics during manufacture assessed by culturing and PCR-DGGE analyses. Int J Food Microbiol 2006, 109:1-8.
23. Knudtson L.M., Hartman P.A. Comparison of fluorescent gentamicin-thallous-carbonate and KF streptococcal agars to enumerate enterococci and fecal streptococci in meats. Appl Environ Microbiol 1993, 59:936-938.
24. Thian T.S., Hartman P.A. Gentamicin-thallous-carbonate medium for isolation of fecal streptococci from foods. Appl Environ Microbiol 1981, 41:724-728.
25. McMahon A.J., Auld C.D., Dale B.A.S., Walls A.D.F., McCormick J.S. Streptococcus bovis septicaemia associated with uncomplicated colonic carcinoma. Br J Surg 1991, 78:883-885.
26. Nielsen S.D., Christensen J.J., Laerkeborg A., Haunso S., Knudsen J.D. Molecular-biological methods of diagnosing colon-related Streptococcus bovis endocarditis. Ugeskr Laeger 2007, 169:610-611.
27. Wentling G.K., Metzger P.P., Dozois E.J., Chua H.K., Krishna M. Unusual bacterial infections and colorectal carcinoma-Streptococcus bovis and Clostridium septicum: report of three cases. Dis Colon Rectum 2006, 49:1223-1227.
28. Gupta A., Madani R., Mukhtar H. Streptococcus bovis endocarditis, a silent sign for colonic tumour. Colorectal Dis 2010, 12:164-171.
29. Kahveci A., Ari E., Arikan H., Koc M., Tuglular S., Ozener C. Streptococcus bovis bacteremia related to colon adenoma in a chronic hemodialysis patient. Hemodial Int 2010, 14:91-93.
30. Kim S.Y., Joo S.I., Yi J., Kim E.C. A case of Streptococcus gallolyticus subsp. gallolyticus infective endocarditis with colon cancer: identification by 16S ribosomal DNA sequencing. Korean J Lab Med 2010, 30:160-165.
31. Murray H.W., Roberts R.B. Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med 1978, 138:1097-1099.
32. Klein R.S., Catalano M.T., Edberg S.C., Casey J.I., Steigbigel N.H. Streptococcus bovis septicemia and carcinoma of the colon. Ann Intern Med 1979, 91:560-562.
33. Reynolds J.G., Silva E., McCormack W.M. Association of Streptococcus bovis bacteremia with bowel disease. J Clin Microbiol 1983, 17:696-697.
34. Pigrau C., Lorente A., Pahissa A., Martinez-Vazquez J.M. Streptococcus bovis bacteremia and digestive system neoplasms. Scand J Infect Dis 1988, 20:459-460.
35. Ruoff K.L., Miller S.I., Garner C.V., Ferraro M.J., Calderwood S.B. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol 1989, 27:305-308.
36. Clarridge J.E., Attorri S.M., Zhang Q., Bartell J. 16S Ribosomal DNA sequence analysis distinguishes biotypes of Streptococcus bovis: Streptococcus bovis biotype II/2 is a separate genospecies and the predominant clinical isolate in adult males. J Clin Microbiol 2001, 39:1549-1552.
37. Gonzlez-Quintela A., Martínez-Rey C., Castroagudín J.F., Rajo-Iglesias M.C., Domínguez-Santalla M.J. Prevalence of liver disease in patients with Streptococcus bovis bacteraemia. J Infect 2001, 42:116-119.
38. Gold J.S., Bayar S., Salem R.R. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Arch Surg 2004, 139:760-765.
39. Lee R.A., Woo P.C.Y., To A.P.C., Lau S.K.P., Wong S.S.Y., Yuen K.-Y. Geographical difference of disease association in Streptococcus bovis bacteraemia. J Med Microbiol 2003, 52:903-908.
40. Zarkin B.A., Lillemoe K.D., Cameron J.L., Effron P.N., Magnuson T.H., Pitt H.A. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990, 211:786-792.
41. Jean S.S., Teng L.J., Hsueh P.R., Ho S.W., Luh K.T. Bacteremic Streptococcus bovis infections at a university hospital, 1992-2001. J Formos Med Assoc 2004, 103:118-123.
42. Corredoira J.C., Alonso M.P., Garcia J.F., et al. Clinical characteristics and significance of Streptococcus salivarius bacteremia and Streptococcus bovis bacteremia: a prospective 16-year study. Eur J Clin Microbiol Infect Dis 2005, 24:250-255.
43. Alazmi W., Bustamante M., O'Loughlin C., Gonzalez J., Raskin J.B. The association of Streptococcus bovis bacteremia and gastrointestinal diseases: a retrospective analysis. Dig Dis Sci 2006, 51:732-736.
44. Giannitsioti E., Chirouze C., Bouvet A., et al. Characteristics and regional variations of group D streptococcal endocarditis in France. Clin Microbiol Infect 2007, 13:770-776.
45. Beck M., Frodl R., Funke G. Comprehensive study of strains previously designated Streptococcus bovis consecutively isolated from human blood cultures and emended description of Streptococcus gallolyticus and Streptococcus infantarius subsp. coli. J Clin Microbiol 2008, 46:2966-2972.
46. Boleij A., Schaeps R.M.J., Tjalsma H. Association between Streptococcus bovis and colon cancer. J Clin Microbiol 2009, 47:516.
47. Corredoira-Sánchez J., García-Garrote F., Rabuñal R., et al. Association between bacteremia due to Streptococcus gallolyticus subsp. gallolyticus (Streptococcus bovis I) and colorectal neoplasia: a case-control study. Clin Infect Dis 2012, 55:491-496.
48. Sharara A.I., Abou Hamdan T., Malli A., et al. Association of Streptococcus bovis endocarditis and advanced colorectal neoplasia: a case-control study. J Dig Dis 2013, 14:382-387.
49. Burns C.A., McCaughey R., Lauter C.B. The association of Streptococcus bovis fecal carriage and colon neoplasia: possible relationship with polyps and their premalignant potential. Am J Gastroenterol 1985, 80:42-46.
50. Klein R.S., Recco R.A., Catalano M.T., Edberg S.C., Casey J.I., Steigbigel N.H. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977, 297:800-802.
51. Darjee R., Gibb A.P. Serological investigation into the association between Streptococcus bovis and colonic cancer. J Clin Pathol 1993, 46:1116-1119.
52. Dubrow R., Edberg S., Wikfors E., et al. Fecal carriage of Streptococcus bovis and colorectal adenomas. Gastroenterology 1991, 101:721-725.
53. Potter M.A., Cunliffe N.A., Smith M., Miles R.S., Flapan A.D., Dunlop M.G. A prospective controlled study of the association of Streptococcus bovis with colorectal carcinoma. J Clin Pathol 1998, 51:473-474.
54. Teitelbaum J.E., Triantafyllopoulou M. Inflammatory bowel disease and Streptococcus bovis. Dig Dis Sci 2006, 51:1439-1442.
55. Tjalsma H., Schöller-Guinard M., Lasonder E., Ruers T.J., Willems H.L., Swinkels D.W. Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int J Cancer 2006, 119:2127-2135.
56. Abdulamir A.S., Hafidh R.R., Mahdi L.K., Al-jeboori T., Abubaker F. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 2009, 9:1-12.
57. Boleij A., Roelofs R., Schaeps R.M., et al. Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients. Cancer 2010, 116:4014-4022.
58. Boleij A., Roelofs R., Danne C., et al. Selective antibody response to Streptococcus gallolyticus pilus proteins in colorectal cancer patients. Cancer Prev Res (Phila) 2012, 5:260-265.
59. Butt J., Romero-Hernández B., Pérez-Gómez B., et al. Association of Streptococcus gallolyticus subspecies gallolyticus with colorectal cancer: serological evidence. Int J Cancer 2016, 138:1670-1679.
60. IARC Schistosomes, Liver Flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans 1994, Vol 61. Lyon.
61. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
62. Suerbaum S., Michetti P. Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186.
63. Correa P., Haenszel W., Cuello C., et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990, 50:4737-4740.
64. Konturek P.C., Konturek S.J., Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 2009, 60:3-21.
65. Wu Q., Yang Z.P., Xu P., Gao L.C., Fan D.M. Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Colorectal Dis 2013, 15:e352-e364.
66. Limburg P.J., Stolzenberg-Solomon R.Z., Colbert L.H., et al. Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. Cancer Epidemiol Biomarkers Prev 2002, 11:1095-1099.
67. Thorburn C.M., Friedman G.D., Dickinson C.J., Vogelman J.H., Orentreich N., Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998, 115:275-280.
68. Jones M., Helliwell P., Pritchard C., Tharakan J., Mathew J. Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship?. World J Surg Oncol 2007, 5. 51-51.
69. Cheng H., Zhang T., Gu W., et al. The presence of Helicobacter pylori in colorectal polyps detected by immunohistochemical methods in children. Pediatr Infect Dis J 2012, 31:364-367.
70. Burnett-Hartman A.N., Newcomb P.A., Potter J.D. Infectious agents and colorectal cancer: a review of Helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus. Cancer Epidemiol Biomarkers Prev 2008, 17:2970-2979.
71. Buc E., Dubois D., Sauvanet P., et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 2013, 8:e56964.
72. Martin H.M., Campbell B.J., Hart C.A., et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004, 127:80-93.
73. Swidsinski A., Khilkin M., Kerjaschki D., et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998, 115:281-286.
74. Maddocks O.D.K., Short A.J., Donnenberg M.S., Bader S., Harrison D.J. Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One 2009, 4:e5517.
75. Arthur J.C., Perez-Chanona E., Mühlbauer M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
76. Bonnet M., Buc E., Sauvanet P., et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 2014, 20:859-867.
77. Cougnoux A., Dalmasso G., Martinez R., et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 2014, 63:1932-1942.
78. Sears C.L. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev 2009, 22:349-369.
79. Goodwin A.C., Shields C.E.D., Wu S., et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci 2011, 108:15354-15359.
80. Wu S., Rhee K.-J., Albesiano E., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15:1016-1022.
81. Ulger Toprak N., Yagci A., Gulluoglu B.M., et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 2006, 12:782-786.
82. Boleij A., Hechenbleikner E.M., Goodwin A.C., et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 2015, 60:208-215.
83. Allen-Vercoe E., Jobin C. Fusobacterium and enterobacteriaceae: important players for CRC?. Immun Lett 2014, 162(2, Part A):54-61.
84. Han Y.W. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol 2015, 23:141-147.
85. Zeller G., Tap J., Voigt A.Y., et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 2014, 10.
86. Castellarin M., Warren R.L., Freeman J.D., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012, 22:299-306.
87. Warren R.L., Freeman D.J., Pleasance S., et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 2013, 1:1-12.
88. Dejea C.M., Wick E.C., Hechenbleikner E.M., et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci 2014, 111:18321-18326.
89. Tahara T., Yamamoto E., Suzuki H., et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014, 74:1311-1318.
90. McCoy A.N., Araújo-Pérez F., Azcárate-Peril A., Yeh J.J., Sandler R.S., Keku T.O. Fusobacterium is associated with colorectal adenomas. PLoS One 2013, 8:e53653.
91. Ito M., Kanno S., Nosho K., et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015, 137:1258-1268.
92. Zackular J.P., Rogers M.A.M., Ruffin M.T., Schloss P.D. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila) 2014, 7:1112-1121.
93. Allen-Vercoe E., Strauss J., Chadee K. Fusobacterium nucleatum. Gut Microbes 2011, 2:294-298.
94. Majowicz S.E., Musto J., Scallan E., et al. The global burden of nontyphoidal salmonella gastroenteritis. Clin Infect Dis 2010, 50:882-889.
95. Crum-Cianflone N.F. Salmonellosis and the gastrointestinal tract: more than just peanut butter. Curr Gastroenterol Rep 2008, 10:424-431.
96. Keithlin J., Sargeant J.M., Thomas M.K., Fazil A. Systematic review and meta-analysis of the proportion of non-typhoidal Salmonella cases that develop chronic sequelae. Epidemiol Infect 2015, 143:1333-1351.
97. Nagaraja V., Eslick G.D. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014, 39:745-750.
98. Ternhag A., Törner A., Svensson Å., Ekdahl K., Giesecke J. Short- and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis 2008, 14:143-148.
99. Jess T., Simonsen J., Nielsen N.M., et al. Enteric salmonella or campylobacter infections and the risk of inflammatory bowel disease. Gut 2011, 60:318-324.
100. Kato I., Boleij A., Kortman G.A., et al. Partial associations of dietary iron, smoking and intestinal bacteria with colorectal cancer risk. Nutr Cancer 2013, 65:169-177.
101. Huycke M.M., Gaskins H.R. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med 2004, 229:586-597.
102. Balamurugan R., Rajendiran E., George S., Samuel G.V., Ramakrishna B.S. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 2008, 23(8 pt 1):1298-1303.
103. Gueimonde M., Ouwehand A., Huhtinen H., Salminen E., Salminen S. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007, 13:3985-3989.
104. Fite A., Macfarlane G.T., Cummings J.H., et al. Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 2004, 53:523-529.
105. Fite A., Macfarlane S., Furrie E., et al. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol 2013, 51:849-856.
106. Ahn J., Segers S., Hayes R.B. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. Carcinogenesis 2012, 33:1055-1058.
107. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
108. Cotillard A., Kennedy S.P., Kong L.C., et al. Dietary intervention impact on gut microbial gene richness. Nature 2013, 500:585-588.
109. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
110. Duca F.A., Sakar Y., Lepage P., et al. Replication of obesity and associated signaling pathways through transfer of microbiota from obese-prone rats. Diabetes 2014, 63:1624-1636.
111. WCRF/AICR Continuous update project report: food, nutrition, physical activity, and the prevention of colorectal cancer. Colorectal Cancer 2011 Rep Lond WCRF/AICR 2011, 1-40.
112. Maukonen J., Saarela M. Human gut microbiota: does diet matter?. Proc Nutr Soc 2015, 74:23-36.
113. David L.A., Maurice C.F., Carmody R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-563.
114. Kim M.-S., Hwang S.-S., Park E.-J., Bae J.-W. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013, 5:765-775.
115. Clarke S.F., Murphy E.F., O'Sullivan O., et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 2014, 63:1913-1920.
116. Mutlu E.A., Gillevet P.M., Rangwala H., et al. Colonic microbiome is altered in alcoholism. Am J Physiol - Gastrointest Liver Physiol 2012, 302:G966-G978.
117. Tuomisto S., Pessi T., Collin P., Vuento R., Aittoniemi J., Karhunen P.J. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol 2014, 14:1-8.
118. Biedermann L., Zeitz J., Mwinyi J., et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One 2013, 8:e59260.
119. Biedermann L., Brulisauer K., Zeitz J., et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis 2014, 20:1496-1501.
120. Kato I., Nechvatal J.M., Dzinic S., Basson M.D., Majumdar A.P., Ram J.L. Smoking and other personal characteristics as potential predictors for fecal bacteria populations in humans. Med Sci Monit 2010, 16:CR1-7.
121. de Martel C., Ferlay J., Franceschi S., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
122. Borges-Canha M., Portela-Cidade J.P., Dinis-Ribeiro M., Leite-Moreira A.F., Pimentel-Nunes P. Role of colonic microbiota in colorectal carcinogenesis: a systematic review. Rev Esp Enferm Dig 2015, 107.
123. Tlaskalova-Hogenova H., Stepankova R., Kozakova H., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011, 8:110-120.
124. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
125. Damman C.J., Miller S.I., Surawicz C.M., Zisman T.L. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation. Am J Gastroenterol 2012, 107:1452-1459.
126. Sokol H., Pigneur B., Watterlot L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105:16731-16736.
127. Veerappan G.R., Betteridge J., Young P.E. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep 2012, 14:324-333.
128. Tirandaz H., Mohammadi E. Efficient tumor targeting by anaerobic butyrate-producing bacteria. Med Hypotheses 2013, 80:675-678.
129. Belenguer A., Holtrop G., Duncan S.H., et al. Rates of production and utilization of lactate by microbial communities from the human colon. FEMS Microbiol Ecol 2011, 77:107-119.
130. Suzuki T., Yoshida S., Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 2008, 100:297-305.
131. Hu S., Dong T.S., Dalal S.R., et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 2011, 6:e16221.
132. Winter J., Nyskohus L., Young G.P., et al. Inhibition by resistant starch of red meat-induced promutagenic adducts in mouse colon. Cancer Prev Res (Phila) 2011, 4:1920-1928.
133. Worthley D.L., Whitehall V.L., Le Leu R.K., et al. DNA methylation in the rectal mucosa is associated with crypt proliferation and fecal short-chain fatty acids. Dig Dis Sci 2011, 56:387-396.
134. Maslowski K.M., Vieira A.T., Ng A., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
135. Rosignoli P., Fabiani R., De Bartolomeo A., et al. Protective activity of butyrate on hydrogen peroxide-induced DNA damage in isolated human colonocytes and HT29 tumour cells. Carcinogenesis 2001, 22:1675-1680.
136. Moore W.E., Moore L.H. Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 1995, 61:3202-3207.
137. Scanlan P.D., Shanahan F., Marchesi J.R. Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. FEMS Microbiol Ecol 2009, 69:213-221.
138. Mantovani A. Cancer: inflaming metastasis. Nature 2009, 457:36-37.
139. Song M., Wu K., Ogino S., Fuchs C.S., Giovannucci E.L., Chan A.T. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 2013, 108:1891-1898.
140. Gradel K.O., Nielsen H.L., Schonheyder H.C., Ejlertsen T., Kristensen B., Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009, 137:495-501.
141. Kumar S. Infection as a risk factor for gallbladder cancer. J Surg Oncol 2006, 93:633-639.
142. Arrach N., Zhao M., Porwollik S., Hoffman R.M., McClelland M. Salmonella promoters preferentially activated inside tumors. Cancer Res 2008, 68:4827-4832.
143. Zhao M., Yang M., Li X.M., et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A 2005, 102:755-760.
144. Collier-Hyams L.S., Zeng H., Sun J., et al. Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-kappa B pathway. J Immunol 2002, 169:2846-2850.
145. Du F., Galan J.E. Selective inhibition of type III secretion activated signaling by the Salmonella effector AvrA. PLoS Pathog 2009, 5:e1000595.
146. Hardt W.D., Galan J.E. A secreted Salmonella protein with homology to an avirulence determinant of plant pathogenic bacteria. Proc Natl Acad Sci U S A 1997, 94:9887-9892.
147. Liao A.P., Petrof E.O., Kuppireddi S., et al. Salmonella type III effector AvrA stabilizes cell tight junctions to inhibit inflammation in intestinal epithelial cells. PLoS One 2008, 3:e2369.
148. Sun J., Hobert M.E., Rao A.S., Neish A.S., Madara J.L. Bacterial activation of beta-catenin signaling in human epithelia. Am J Physiol Gastrointest Liver Physiol 2004, 287:G220-G227.
149. Ye Z., Petrof E.O., Boone D., Claud E.C., Sun J. Salmonella effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination. Am J Pathol 2007, 171:882-892.
150. Liu X., Lu R., Wu S., Sun J. Salmonella regulation of intestinal stem cells through the Wnt/beta-catenin pathway. FEBS Lett 2010, 584:911-916.
151. Lu R., Wu S., Zhang Y., et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis 2014.
152. Belcheva A., Irrazabal T., Robertson S.J., et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 2014, 158:288-299.
153. Bongers G., Pacer M.E., Geraldino T.H., et al. Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. J Exp Med 2014, 211:457-472.
154. Keku T.O., Dulal S., Deveaux A., Jovov B., Han X. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2015, 308:G351-G363.
155. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
156. Grivennikov S.I., Wang K., Mucida D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
157. Round J.L., Mazmanian S.K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Nat Acad Sci U S A 2010, 107:12204-12209.
158. Round J.L., O'Connell R.M., Mazmanian S.K. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010, 34:J220-J225.
159. Schwabe R.F., Jobin C. The microbiome and cancer. Nat Rev Cancer 2013, 13:800-812.
160. O'Keefe S.J., Li J.V., Lahti L., et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 2015, 6:6342.
161. Wallace B.D., Wang H., Lane K.T., et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010, 330:831-835.
162. Pennisi E. Biomedicine. Cancer therapies use a little help from microbial friends. Science 2013, 342:921.
163. Sivan A., Corrales L., Hubert N., et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015, 350:1084-1089.
164. Schieber A.M., Lee Y.M., Chang M.W., et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science 2015, 350:558-563.
165. Bindels L.B., Neyrinck A.M., Salazar N., et al. Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia in mice. PLoS One 2015, 10:e0131009.